{"id":745384,"date":"2016-05-12T07:30:00","date_gmt":"2016-05-12T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/"},"modified":"2025-11-07T01:25:52","modified_gmt":"2025-11-07T06:25:52","slug":"merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/","title":{"rendered":"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association"},"content":{"rendered":"<p class=\"bwalignc\">       Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA<sup>\u00ae<\/sup>        (sitagliptin) Also to Be Presented     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that researchers will present data from clinical trials<br \/>\n      of its investigational diabetes pipeline, JANUVIA<sup>\u00ae<\/sup><br \/>\n      (sitagliptin), and new real-world research in more than 20 scientific<br \/>\n      data presentations at the 76<sup>th<\/sup> Scientific Sessions of the<br \/>\n      American Diabetes Association (ADA) being held in New Orleans, June<br \/>\n      10-14, 2016. New investigational clinical trial data to be presented<br \/>\n      include the first Phase 3 results for ertugliflozin, an oral SGLT2<br \/>\n      inhibitor in development with Pfizer for patients with type 2 diabetes,<br \/>\n      and for MK-1293, Merck\u2019s follow-on biologic insulin glargine candidate<br \/>\n      being evaluated for patients with type 1 and type 2 diabetes. Additional<br \/>\n      analyses will also be presented from the TECOS (Trial Evaluating<br \/>\n      Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of<br \/>\n      JANUVIA.\n    <\/p>\n<p>\n      \u201cAt Merck, we have a long-term commitment to diabetes research and<br \/>\n      advancing the care of people living with diabetes around the world,\u201d<br \/>\n      said Peter Stein, M.D., vice president, late stage development, diabetes<br \/>\n      and endocrinology, Merck. \u201cWe look forward to presenting new clinical<br \/>\n      trial data and results of several studies from real-world settings at<br \/>\n      this year\u2019s American Diabetes Association Scientific Sessions.\u201d\n    <\/p>\n<p>\n      <b>Indications and Usage for JANUVIA<\/b><sup><b> <\/b><\/sup><b>(sitagliptin)<br \/>\n      25 mg, 50 mg and 100 mg tablets<\/b>\n    <\/p>\n<p>\n      JANUVIA is indicated, as an adjunct to diet and exercise, to improve<br \/>\n      glycemic control in adults with type 2 diabetes mellitus. JANUVIA should<br \/>\n      not be used in patients with type 1 diabetes or for the treatment of<br \/>\n      diabetic ketoacidosis. JANUVIA has not been studied in patients with a<br \/>\n      history of pancreatitis. It is unknown whether patients with a history<br \/>\n      of pancreatitis are at increased risk of developing pancreatitis while<br \/>\n      taking JANUVIA.\n    <\/p>\n<p>\n      <b>Selected Important Risk Information about JANUVIA<\/b>\n    <\/p>\n<p>\n      JANUVIA is contraindicated in patients with a history of a serious<br \/>\n      hypersensitivity reaction to sitagliptin, such as anaphylaxis or<br \/>\n      angioedema.\n    <\/p>\n<p>\n      There have been postmarketing reports of acute pancreatitis, including<br \/>\n      fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients<br \/>\n      taking JANUVIA. After initiating JANUVIA, observe patients carefully for<br \/>\n      signs and symptoms of pancreatitis. If pancreatitis is suspected,<br \/>\n      promptly discontinue JANUVIA and initiate appropriate management. It is<br \/>\n      unknown whether patients with a history of pancreatitis are at increased<br \/>\n      risk of developing pancreatitis while taking JANUVIA.\n    <\/p>\n<p>\n      Selected Important Risk Information about JANUVIA continued below.\n    <\/p>\n<p>\n      <span class=\"bwuline\"><b>Abstracts<\/b><\/span>\n    <\/p>\n<p>\n      Select abstracts to be presented include the following:\n    <\/p>\n<p>\n      <b>Ertugliflozin<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Ertugliflozin: Glycemic control as monotherapy in patients with T2DM<br \/>\n        (Abstract #130-LB, Sunday, June 12, 12:00-2:00 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Effect of ertugliflozin plus sitagliptin on glycemic control vs.<br \/>\n        either treatment alone in subjects with T2DM inadequately controlled<br \/>\n        with metformin (Abstract #125-LB, Sunday, June 12, 12:00-2:00 p.m. CT)\n      <\/li>\n<\/ul>\n<p>\n      Ertugliflozin (MK-8835) is being developed in collaboration with Pfizer,<br \/>\n      Inc. for the treatment of patients with type 2 diabetes.\n    <\/p>\n<p>\n      <b>MK-1293<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Efficacy and safety of MK-1293 insulin glargine compared with<br \/>\n        originator insulin glargine (Lantus) in type 2 diabetes (T2D)<br \/>\n        (Abstract #926-P, Saturday, June 11, 11:30 a.m.-1:30 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        A single-dose euglycemic clamp study in subjects with type 1 diabetes<br \/>\n        demonstrating pharmacokinetic and pharmacodynamic similarity between<br \/>\n        MK-1293 insulin glargine and originator insulin glargine (Lantus)<br \/>\n        (Abstract #946-P, Saturday, June 11, 11:30 a.m.-1:30 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Efficacy and safety of MK-1293 insulin glargine compared with<br \/>\n        originator insulin glargine (Lantus) in type 1 diabetes (T1D)<br \/>\n        (Abstract #296-OR, Monday, June 13, 9:30-9:45 a.m. CT)\n      <\/li>\n<\/ul>\n<p>\n      MK-1293 is being developed by Merck for the treatment of patients with<br \/>\n      type 1 and type 2 diabetes,&nbsp;and Samsung Bioepis is partially funding its<br \/>\n      development.\n    <\/p>\n<p>\n      <b>JANUVIA<\/b><sup><b>\u00ae<\/b><\/sup><b> (sitagliptin)<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Assessing the safety of sitagliptin in patients with type 2 diabetes<br \/>\n        and chronic kidney disease in the Trial Evaluating Cardiovascular<br \/>\n        Outcomes with Sitagliptin (TECOS) (Abstract #1181-P, Sunday, June 12,<br \/>\n        12:00-2:00 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        A pooled analysis: Reduction of hypoglycemic event rate with<br \/>\n        sitagliptin compared with sulfonylurea (Abstract #1112-P, Sunday, June<br \/>\n        12, 12:00-2:00 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Sitagliptin and risk of fractures in type 2 diabetes: Results from the<br \/>\n        TECOS trial (Abstract #587-P, Monday, June 13, 12:00-2:00 p.m. CT)\n      <\/li>\n<\/ul>\n<p>\n      <b>Real-World Data \u2013 Type 2 Diabetes<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Clinical inertia in patients with type 2 diabetes mellitus at a large,<br \/>\n        integrated, U.S. health care system (Abstract #1442-P, Sunday, June<br \/>\n        12, 12:00-2:00 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Frequency of documented hypoglycemia among U.S. patients with type 2<br \/>\n        diabetes and insulin treatment (Abstract #396-P, Sunday, June 12,<br \/>\n        12:00-2:00 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Direct medical costs of severe hypoglycemic events among type 2<br \/>\n        diabetes patients in UK (Abstract #1464-P, Sunday, June 12, 12:00-2:00<br \/>\n        p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        History of hypoglycemic events more than knowledge predicts fear of<br \/>\n        hypoglycemia in T2DM (Abstract #400-P, Sunday, June 12, 12:00-2:00<br \/>\n        p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        A retrospective cohort study on conversion to diabetes among a<br \/>\n        prediabetic adult population in China (Abstract #1423-P, Sunday, June<br \/>\n        12, 12:00-2:00 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Survival in people with type 2 diabetes with lower glycosylated<br \/>\n        hemoglobin (Abstract #173-OR, Saturday, June 11, 5:30-5:45 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        External validation of the UK Prospective Diabetes Study risk<br \/>\n        equations in 14,740 Israel type 2 diabetes patients (Abstract #354-OR,<br \/>\n        Monday, June 13, 5:30-5:45 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Intensification of therapy and time until A1c goal attainment among<br \/>\n        patients with new-onset type 2 diabetes (T2D) who fail metformin<br \/>\n        monotherapy within a large integrated health system (Abstract #363-OR,<br \/>\n        Monday, June 13, 5:45-6:00 p.m. CT)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Prevalence of diabetes in U.S. Medicaid pediatric population,<br \/>\n        2002-2013 (Abstract #156-LB, Sunday, June 12, 12:00-2:00 p.m. CT)\n      <\/li>\n<\/ul>\n<p>\n      For more information, including a complete list of abstract titles at<br \/>\n      the meeting, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fprofessional.diabetes.org%2Fmeeting%2Fscientific-sessions%2F76th-scientific-sessions&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=http%3A%2F%2Fprofessional.diabetes.org%2Fmeeting%2Fscientific-sessions%2F76th-scientific-sessions&amp;index=1&amp;md5=e4f8bc67256d3e45de42433d46688d93\" rel=\"nofollow\">http:\/\/professional.diabetes.org\/meeting\/scientific-sessions\/76th-scientific-sessions<\/a>.\n    <\/p>\n<p>\n      <b>Selected Important Risk Information about JANUVIA (continued)<\/b>\n    <\/p>\n<p>\n      Assessment of renal function is recommended prior to initiating JANUVIA<br \/>\n      and periodically thereafter. A dosage adjustment is recommended in<br \/>\n      patients with moderate or severe renal insufficiency and in patients<br \/>\n      with end-stage renal disease requiring hemodialysis or peritoneal<br \/>\n      dialysis. Caution should be used to ensure that the correct dose of<br \/>\n      JANUVIA is prescribed.\n    <\/p>\n<p>\n      There have been postmarketing reports of worsening renal function,<br \/>\n      including acute renal failure, sometimes requiring dialysis. A subset of<br \/>\n      these reports involved patients with renal insufficiency, some of whom<br \/>\n      were prescribed inappropriate doses of sitagliptin.\n    <\/p>\n<p>\n      When JANUVIA was used in combination with a sulfonylurea or insulin,<br \/>\n      medications known to cause hypoglycemia, the incidence of hypoglycemia<br \/>\n      was increased over that of placebo. Therefore, a lower dose of<br \/>\n      sulfonylurea or insulin may be required to reduce the risk of<br \/>\n      hypoglycemia.\n    <\/p>\n<p>\n      The incidence (and rate) of hypoglycemia based on all reports of<br \/>\n      symptomatic hypoglycemia were: 12.2% (0.59 episodes\/patient-year) for<br \/>\n      JANUVIA 100 mg in combination with glimepiride (with or without<br \/>\n      metformin), 1.8% (0.24 episodes\/patient-year) for placebo in combination<br \/>\n      with glimepiride (with or without metformin), 15.5% (1.06<br \/>\n      episodes\/patient-year) for JANUVIA 100 mg in combination with insulin<br \/>\n      (with or without metformin), and 7.8% (0.51 episodes\/patient-year) for<br \/>\n      placebo in combination with insulin (with or without metformin).\n    <\/p>\n<p>\n      There have been postmarketing reports of serious hypersensitivity<br \/>\n      reactions in patients treated with JANUVIA, such as anaphylaxis,<br \/>\n      angioedema, and exfoliative skin conditions including Stevens-Johnson<br \/>\n      syndrome. Onset of these reactions occurred within the first 3 months<br \/>\n      after initiation of treatment with JANUVIA, with some reports occurring<br \/>\n      after the first dose. If a hypersensitivity reaction is suspected,<br \/>\n      discontinue JANUVIA, assess for other potential causes for the event,<br \/>\n      and institute alternative treatment for diabetes.\n    <\/p>\n<p>\n      Angioedema has also been reported with other dipeptidyl peptidase-4<br \/>\n      (DPP-4) inhibitors. Use caution in a patient with a history of<br \/>\n      angioedema with another DPP-4 inhibitor because it is unknown whether<br \/>\n      such patients will be predisposed to angioedema with JANUVIA<sup><b>\u00ae<\/b><\/sup>.\n    <\/p>\n<p>\n      There have been postmarketing reports of severe and disabling arthralgia<br \/>\n      in patients taking DPP-4 inhibitors. The time to onset of symptoms<br \/>\n      following initiation of drug therapy varied from 1 day to years.<br \/>\n      Patients experienced relief of symptoms upon discontinuation of the<br \/>\n      medication. A subset of patients experienced a recurrence of symptoms<br \/>\n      when restarting the same drug or a different DPP-4 inhibitor. Consider<br \/>\n      DPP-4 inhibitors as a possible cause for severe joint pain and<br \/>\n      discontinue drug if appropriate.\n    <\/p>\n<p>\n      There have been no clinical studies establishing conclusive evidence of<br \/>\n      macrovascular risk reduction with JANUVIA or with any other antidiabetic<br \/>\n      drug.\n    <\/p>\n<p>\n      In clinical studies, the adverse reactions reported, regardless of<br \/>\n      investigator assessment of causality, in \u22655% of patients treated with<br \/>\n      JANUVIA as monotherapy and in combination therapy and more commonly than<br \/>\n      in patients treated with placebo, were upper respiratory tract<br \/>\n      infection, nasopharyngitis, and headache.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=85b0d3ef75e699324cef686699b419c8\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=c26d8b9613c83e13dc950a690ecf1bd5\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=9c44f9d7d38381c98699c3468ba3edb7\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=ed524c92de001573e568c7693be48d74\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=28f56c242c65811f6f23d04c5fefc642\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=b633b1d4962475967efba7b405ee558f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for JANUVIA<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      (sitagliptin) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_pi.pdf&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_pi.pdf&amp;index=8&amp;md5=2535336ec7cf73bb900ee4259497ecde\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/j\/januvia\/januvia_pi.pdf<\/b><\/a><b><br \/>\n      and Medication Guide for JANUVIA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_mg.pdf&amp;esheet=51341183&amp;newsitemid=20160512005723&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fj%2Fjanuvia%2Fjanuvia_mg.pdf&amp;index=9&amp;md5=563c935a396a79d48791c0e075b0e9a2\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/j\/januvia\/januvia_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160512005723r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>Kristen Drake,        908-236-4223<br \/>or<br \/>Investors:<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA \u00ae (sitagliptin) Also to Be Presented Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA\u00ae (sitagliptin), and new real-world research in more than 20 scientific data presentations at the 76th Scientific Sessions of the American Diabetes Association (ADA) being held in New Orleans, June 10-14, 2016. New investigational clinical trial data to be presented include the first Phase 3 results for ertugliflozin, an oral SGLT2 inhibitor in development with Pfizer for patients with type 2 diabetes, and for MK-1293, Merck\u2019s follow-on biologic insulin glargine candidate being evaluated for patients with type 1 and type 2 diabetes. Additional analyses will also be presented from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745384","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA \u00ae (sitagliptin) Also to Be Presented Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA\u00ae (sitagliptin), and new real-world research in more than 20 scientific data presentations at the 76th Scientific Sessions of the American Diabetes Association (ADA) being held in New Orleans, June 10-14, 2016. New investigational clinical trial data to be presented include the first Phase 3 results for ertugliflozin, an oral SGLT2 inhibitor in development with Pfizer for patients with type 2 diabetes, and for MK-1293, Merck\u2019s follow-on biologic insulin glargine candidate being evaluated for patients with type 1 and type 2 diabetes. Additional analyses will also be presented from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\\\/\",\"name\":\"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-05-12T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association - Merck.com","og_description":"Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA \u00ae (sitagliptin) Also to Be Presented Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA\u00ae (sitagliptin), and new real-world research in more than 20 scientific data presentations at the 76th Scientific Sessions of the American Diabetes Association (ADA) being held in New Orleans, June 10-14, 2016. New investigational clinical trial data to be presented include the first Phase 3 results for ertugliflozin, an oral SGLT2 inhibitor in development with Pfizer for patients with type 2 diabetes, and for MK-1293, Merck\u2019s follow-on biologic insulin glargine candidate being evaluated for patients with type 1 and type 2 diabetes. Additional analyses will also be presented from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:52+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/","name":"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-05-12T07:30:00+00:00","dateModified":"2025-11-07T06:25:52+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-phase-3-data-on-investigational-medicines-ertugliflozin-and-mk-1293-at-the-76th-scientific-sessions-of-the-american-diabetes-association\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0148def2-2ad6-4d8d-b3dc-69e5bcdc476f","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Present-Phase-3-Data-on-Investigational-Medicines-Ertugliflozin-and-MK-1293-at-the-76th-Scientific-Sessions-of-the-American--UOM26.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745384\/revisions"}],"predecessor-version":[{"id":3674780,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745384\/revisions\/3674780"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745384"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}